ClinicalTrials.gg
RecruitingNCT05011227Updated Mar 6, 2024

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

A Phase 2 interventional study of Camrelizumab and Chemotherapy in Recurrent Nasopharyngeal Carcinoma, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Eye & ENT Hospital of Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing camrelizumab in Nasopharyngeal Carcinoma — 9 open to participants now, 11 under way, 2 of them phase 3. camrelizumab · Nasopharyngeal Carcinoma.

Planned enrollment
7th of 17
100 · median 58
Started
2021
with 2 others
Phase 2
13 of 17
7 open now
Primary completion
2025-08
later than 8 of 10 live
Registered
10th of 17
by date
Lead sponsor
1 of 17
Eye & ENT Hospital of Fudan University

Among the 17 studies testing camrelizumab in Nasopharyngeal Carcinoma, this one is the 7th largest by planned enrollment, is one of 3 that started in 2021, is one of 13 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 10th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

9 of the 17 studies testing camrelizumab in Nasopharyngeal Carcinoma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing camrelizumab in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.

03

Conditions studied

  • Recurrent Nasopharyngeal Carcinoma

Keywords

  • endoscopic surgery
  • Inductive chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed recurrent nasopharyngeal carcinoma
  • American Joint Committee on Cancer recurrent rT2(recurrent T2)(including deep parapharyngeal space), recurrent T3, recurrent T4 which can be surgically removed
  • Age ≥18 years old
  • signed
  • With or without lymph node , which can be surgically removed
  • No massive hemorrhage risk recently
  • No distant metastasis
  • ≥6 months from initial radiotherapy to recurrence
  • Radical radiation only once
  • Sufficient organ function
  • score 0-2

Exclusion criteria

Exclusion Criteria:

  • With a history of allergic to platinum drugs and similar compounds
  • Evidence of distant or radiation encephalopathy or (LMD)
  • Have received radioactive seed implantation in the treatment area
  • Suffer from uncontrolled disease which could interfere with treatment
  • Suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.)
  • The patient has surgical : such as severe cardiopulmonary disease, coagulation dysfunction and so on
  • The patients have diseases
  • The patient is using agents or systemic to achieve the purpose of immunosuppression (dose>10mg/day prednisone or other), and continues to use it within 2 weeks before the first administration
  • Severe allergic reaction to other monoclonal antibodies
  • Previously received monoclonal antibody, CTLA-4 monoclonal antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway) treatment
  • have been inoculated within 4 weeks before the first administration or during the study period
  • The patient has any situation that may hinder study compliance or the safety during the study period
  • Existence of serious neurological or psychiatric diseases, such as dementia and seizures
  • Uncontrolled active infection
  • Pregnant or breastfeeding women
  • Those who have no personal freedom and independent capacity for civil conduct
  • There are other situations that are not suitable for entry into the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Camrelizumab and chemotherapy combined with endoscopic surgery

    Camrelizumab and chemotherapy combined with endoscopic surgery

    Drug: Camrelizumab · Drug: Chemotherapy · Procedure: endoscopic surgery

Interventions

  • 2 cycles Camrelizumab before endoscopic surgery and one year after

  • DrugChemotherapy

    2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery

  • Procedureendoscopic surgery

    standard endoscopic surgery for recurrent nasopharyngeal carcinoma

06

What researchers measure

Primary outcomes

  1. Overall Survival

    2 year Overall Survival rate

    Time frame: From date of first treatment until the date of death from any cause, up to 4 years.

Secondary outcomes

  1. Local recurrence free survival

    the date of first treatment to local failure or death

    Time frame: From date of first treatment until the date of local recurrence or death from any cause, up to 4 years.

  2. Progression free survival

    the date of first treatment to the first recording of disease progression or death from any cause.

    Time frame: From date of first treatment until the date of disease progression or death from any cause, up to 4 years.

  3. Rate of negative margin

    negative margin rate according to pathology report

    Time frame: At the time of pathology reporting, util the pathology report of last subject was completed, up to 2.5 years.

  4. distant metastasis free survival

    the date of first treatment to distant metastasis or death

    Time frame: From date of first treatment until the date of distant metastasis or death from any cause, up to 4 years.

  5. pathologic complete remission

    pathologic complete remission

    Time frame: At the time of pathology reporting,util the pathology report of last subject was completed, up to 2.5 years.

Other outcomes

  1. quality of life-(EORTC QLQ) - C30 version3.0

    using European Organisation for Research and Treatment of Cancer quality of life questionaire(EORTC QLQ) - C30 version3.0. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: From date of first treatment to the end of study, at each visit, up to 4 years.

  2. quality of life-(EORTC QLQ) - H&N35

    using European Organisation for Research and Treatment of Cancer quality of life questionaire(EORTC QLQ)- H\&N35,All of the scales and single-item measures range in score from 0 to 100. For all the scales and single-items a high score represents a high level of symptomatology or problems.

    Time frame: From date of first treatment to the end of study, at each visit, up to 4 years.

  3. adverse effect

    Using CTCAE Version5.0 to evaluate related adverse effect

    Time frame: From date of first treatment to the end of study, up to 4 years.

  4. immune related adverse effect

    Using CTCAE Version5.0 to evaluate immune related adverse effect

    Time frame: From date of first treatment to the end of study, up to 4 years.

07

Study locations

1 of 7 sites recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
    Not yet recruiting
    • Desheng Wang, MD · Contact
    • Haichun Lai, MD · Contact
    • Desheng Wang · Principal investigator
  • Fujian Provincial Hospital
    Fuzhou, Fujian, China
    Not yet recruiting
    • Shaopeng Huang · Contact
    • Shaopeng Huang · Principal investigator
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong, China
    Not yet recruiting
    • Yongtian Lu · Contact
    • Yongtian Lu · Principal investigator
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi, China
    Not yet recruiting
    • Jingjin Weng, PhD · Contact
    • Shenhong Qu · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Not yet recruiting
    • Jing Ye, MD · Contact
    • Jing Ye · Principal investigator
  • Eye& ENT Hospital, Fudan University
    Shanghai, Shanghai 200031, China
    Recruiting
    • Li Yan, MD · Contactyanl13@fudan.edu.cn · 13761720601
    • Xiaoshen Wang, PHD · Sub investigator
  • Shanghai Zhongshan Hospital,Fudan University
    Shanghai, Shanghai, China
    Not yet recruiting
    • Xinsheng Huang · Contact
    • Xinsheng Huang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Aug 2025, 48 months after the start.

Of 128 non-industry phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 48 months is close to that.

Counting every sponsor, half of 143 studies reached it within 43 months; a quarter within 28 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2021
First posted
Aug 18, 2021
StartActual
Aug 10, 2021
Primary completionEst.
Aug 10, 2025
CompletionEst.
Aug 10, 2025
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05011227
Responsible party
Sponsor
First posted
Aug 18, 2021
Start date
Aug 10, 2021
Primary completion
Aug 10, 2025 (estimated)
Completion
Aug 10, 2025 (estimated)
Last update
Mar 6, 2024

Study contacts

Xiaole Song, MD
Contact
jxfxsxl@163.com
15821388769
Hongmeng Yu, MD,PHD
principal investigator · Eye&ENT Hospital,Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion